Hayashi, Hiroki
Sun, Jiao
Yanagida, Yuka
Otera, Takako
Tai, Jiayu A.
Nishikawa, Tomoyuki
Yamashita, Kunihiko
Sakaguchi, Naoki
Yoshida, Shota
Baba, Satoshi
Chang, Chin Yang
Shimamura, Munehisa
Okamoto, Sachiko
Amaishi, Yasunori
Chono, Hideto
Mineno, Junichi
Rakugi, Hiromi
Morishita, Ryuichi
Nakagami, Hironori
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP20nk0101602 and JP21nf0101623h102)
Article History
Received: 8 March 2023
Accepted: 6 August 2023
First Online: 10 August 2023
Competing interests
: The Department of Health Development and Medicine is an endowed department supported by Anges, Daicel, and FunPep. The Department of Clinical Gene Therapy was financially supported by Novartis, AnGes, Shionogi, Boeringher, Fancl, Saisei Mirai Clinics, Rohto, and FunPep. The Department of Gene and Stem Cell Regenerative Therapy is financially supported by AS medical support. R.M. is a stockholder for FunPep and AnGes. T.O. is an employee of AnGes. K.Y. and N.S. are the employees of Daicel. S.O, Y.A, H.C, and J.M. were employees of Takara Bio. The funders provided support in the form of salaries for the authors. However, they did not have any additional role in the study design, data analysis, decision to publish, or preparation of the manuscript. All other authors declare no competing interests.